A comprehensive view of sanofi sa. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Sanofi's rilzabrutinib meets primary endpoint in Phase 3 LUNA 3 study for immune thrombocytopenia; potential for clinically beneficial treatment of several immune diseases underscored, with regulatory submissions in the US and EU expected by year-end
Published: April 23, 2024 by Sanofi SA
Sanofi SA Champions Early Diagnosis and Quality of Life in Rare Diseases and Chronic Conditions, Impacting Over 30 Million in Europe
Published: April 20, 2024 by Industry Intelligence Inc.
Sanofi's frexalimab shows high efficacy in 48-week Phase 2 trial for multiple sclerosis, with an annualized relapse rate of 0.04 for high-dose variants; Phase 3 studies have begun for both relapsing and non-relapsing secondary progressive MS
Published: April 17, 2024 by Sanofi SA
Sanofi announces undisclosed number of layoffs as part of a new vision to become an immunoscience powerhouse; head of R&D revealed the company's plans following an extensive review, leading to a 'pipeline reprioritization project'
Published: April 05, 2024 by FierceBiotech
Sanofi SA Boosts Public Health with Adolescent Immunization Advocacy and Pioneers in Rare Disease Management while Capitalizing on E-Commerce Trends
Published: April 03, 2024 by Industry Intelligence Inc.

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count